Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults
Conditions
Interventions
ELA026
ELA026
Locations
2
United States
Celerion
Lincoln, Nebraska, United States
Medical University of Vienna
Vienna, Austria
Start Date
October 18, 2021
Primary Completion Date
November 20, 2023
Completion Date
November 20, 2023
Last Updated
March 27, 2024
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Electra Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions